Top 5 Most-Read Myasthenia Gravis Articles of 2023
December 18th 2023In our coverage of myasthenia gravis this year, the top developments show the effects of COVID-19 continue to be uncovered, a new FDA approval for generalized disease, and assessing patient outcomes following uncontrolled disease and respiratory distress.
Read More
Australian Government Pricing Policy Saved Over $6 Million After Etanercept Biosimilar Launched
December 16th 2023The government of Australia’s pricing policy links the price of new medications with similar safety and efficacy, resulting in significant savings over the first 3 years after the etanercept biosimilar Brenzys was introduced.
Read More
What We’re Reading: Inflation Penalties; Melanoma Vaccine; Respiratory Vaccine Coverage
December 15th 2023A vaccine is showing promising results in treating melanoma; the Biden administration will implement inflation penalties on dozens of drugmakers to reduce out-of-pocket costs for Medicare recipients; the CDC issued an alert urging health care providers to increase immunization coverage for influenza, COVID-19, and respiratory syncytial virus (RSV).
Read More
Patients With Multiple Myeloma Lack Awareness of CAR T-Cell Therapy, Research Says
December 15th 2023The results indicated that a substantial proportion of patients, particularly in rural, less educated, and elderly demographics, are insufficiently informed about novel MM treatments, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody alternatives.
Read More
FDA Approves Belzutifan for Advanced RCC After PD-1 or PD-L1 Inhibition and a VEGF-TKI
December 15th 2023The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
Read More
Frontline Serplulimab Plus Chemo Provides Consistent Survival Benefit in Squamous NSCLC
December 15th 2023The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.
Read More
FDA Extends Review Time for Investigational Duchenne Agent Givinostat
December 15th 2023Givinostat, a histone deacetylase inhibitor from Italfarmaco, was supported by data from the phase 3 EPIDYS study, a randomized, double-blind, placebo-controlled, multicenter trial investigating the agent vs placebo.
Read More
AHIP Report Touts Medicare Advantage’s Quality Edge, but Hospital Concerns Persist
December 14th 2023A new report from AHIP shows that Medicare Advantage outperformed traditional Medicare on several clinical quality measures, including preventive screenings. However, debate continues over these plans’ cost efficiency and impact on the financial sustainability of rural hospitals.
Read More
Adding Navy Beans to Diet Can Enhance Gut Microbiome, BE GONE Trial Finds
December 14th 2023New research shows that adding navy beans to one’s usual diet may be a viable dietary strategy for modulating the gut microbiome and regulating host markers associated with metabolic obesity and colorectal cancer.
Read More
The rate of invasive pneumococcal disease in children plummeted by 72% from 2002 to 2021; health care spending in the United States rose 4.1% in 2022 to $4.5 trillion; roughly two-thirds of Americans who have a mental health condition were unable to access treatment in 2021 despite having health insurance.
Read More
What We’re Reading: Childhood Obesity Counseling; Humana Lawsuit; AI Use Concern
December 13th 2023The US Preventive Services Task Force (USPSTF) recommended that children with obesity receive intensive counseling at age 6 to promote healthy diet and exercise habits; a new survey found that the majority of American patients are wary of their doctors using artificial intelligence (AI); a class-action lawsuit was filed Tuesday against health insurer Humana for using an AI algorithm that systemically denies seniors rehabilitation care recommended by their doctors.
Read More